*To the Editor*:

In a recent issue of the *Journal*, we read the article by Lalgudi Ganesan and colleagues entitled "Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome: A Randomized Controlled Trial" ([@bib1]). We now have two small randomized controlled trials in patients with acute respiratory distress syndrome (ARDS) comparing airway pressure release ventilation (APRV) with low-V[t]{.smallcaps} lung-protective ventilation (LTV). The APRV research we previously conducted in a population of adult subjects showed that APRV had a better effect than LTV in adult patients with ARDS. Subsequently, Lalgudi Ganesan and colleagues performed an APRV study in pediatric subjects and their trial was terminated early because of high mortality in the APRV group. Does APRV treatment for ARDS really differ between adults and children? We think there are some issues that are worth discussing.

First, some baseline characteristics were unbalanced between the groups in Lalgudi Ganesan and colleagues' study. We found that there was a difference in the percentage of males and females between their APRV and LTV groups (65.4% vs. 34.6%, *P* = 0.027), and the severity of ARDS at enrollment also differed between the two groups (*P* = 0.056). Patients with different severities of ARDS have different responses to various treatments ([@bib2], [@bib3]); hence, these differences must be considered in the baseline balance between two groups. Furthermore, not only the severity but also the type of ARDS will produce a difference in treatment effect. In our recent research, we performed a secondary analysis of our original study ([@bib4]), and we found that APRV has different effects on pulmonary and extrapulmonary ARDS. Our study showed that patients with extrapulmonary ARDS had more ventilator-free days at 28 days than those with pulmonary ARDS (14 vs. 20 d, *P* \< 0.05) when early APRV was administered to adults in the ICU ([Table 1](#tbl1){ref-type="table"}). Rather than generalizing ARDS as a single phenotype, we need to stratify patients according to their ARDS physiology, and this may be a major point that greatly affected the results of their study.

###### 

Outcome Variables of Patients Who Underwent Airway Pressure Release Ventilation in Our Recent Study

  Outcome Variables                      Pulmonary ARDS (*n* = *26*)   Extrapulmonary ARDS (*n* = *45*)   *P* Value
  ------------------------------------- ----------------------------- ---------------------------------- -----------
  No. of ventilator-free days at 28 d         14.0 (0.0--20.5)                20.0 (15.0--22.5)             0.046
  No. of days of ventilation                  11.0 (5.0--18.0)                 7.0 (5.0--10.0)              0.082
  Length of ICU stay, d                       17.0 (7.8--23.5)                 12.0 (7.5--18.5)             0.162
  Length of hospital stay, d                  12.0 (7.5--18.5)                20.0 (11.0--32.5)             0.844

*Definition of abbreviation*: ARDS = acute respiratory distress syndrome.

All data were analyzed by Mann-Whitney *U* tests, and a two-sided *P* value of \<0.05 was considered statistically significant. Data are shown as median (interquartile range).

Second, we recommend setting initial parameters based on the pathophysiology of patients, despite the current lack of standard APRV settings. In our previous study ([@bib4]), the initial parameters we set were based on the patients' measured plateau airway pressure (Pplat), compliance, and other respiratory mechanics indicators, and individualized adjustments were made according to the actual situation of the patients. In their study, Lalgudi Ganesan and colleagues set the high pressure time at 4 seconds, and if the Pplat could not be reliably determined, they used reference ranges to set Phigh. Furthermore, when the parameters needed to be adjusted, they also directly adjusted the parameters to a certain range. Additionally, the physiological characteristics of the respiratory system in children can be different for different ages. For example, the younger children are, the faster they breathe, and the smaller their V[t]{.smallcaps}. Compared with 12-year-olds, 2-month-old children have higher airway resistance, higher chest wall compliance, less alveolar area, and more abdominal breathing. All of this means that children of different ages should be ventilated in different ways, and individual APRV settings are required. Thus, we believe that the initial parameters that were inconsistent with the pathophysiology of the patients may have caused the worse outcomes in the APRV group.

Third, the type of ventilator used is an important factor that is often overlooked in our daily research. In our previous study, we used a Puritan Bennett 840 ventilator (Medtronic) to deliver APRV, whereas Lalgudi Ganesan and colleagues used Hamilton Galileo (Hamilton Medical) or Servo I (MAQUET) ventilators. Different ventilators have different features---for instance, at the end of high pressure time and with the expiratory phase of a spontaneous breath, the Puritan Bennett 840 could synchronize the transition from Phigh to Plow ([@bib5]). We suggest that using a single ventilator for all patients in a trial might minimize the bias caused by different types of ventilators.

Finally, we are delighted to participate in this "APRV debate." To ensure a more reasonable use of APRV in adult and pediatric patients with ARDS, more evidence is needed.

Supported by the National Natural Science Foundation of China (grant 81873929).

Originally Published in Press as DOI: [10.1164/rccm.201901-0179LE](http://dx.doi.org/10.1164/rccm.201901-0179LE) on May 21, 2019

[**[Author disclosures](http://www.atsjournals.org/doi/suppl/10.1164/rccm.201901-0179LE/suppl_file/disclosures.pdf)**]{.ul} are available with the text of this letter at [www.atsjournals.org](http://www.atsjournals.org).

[^1]: These authors contributed equally to this work and are co--first authors.
